Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial symbols : Sny save search
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
Published: 2024-04-16 (Crawled : 23:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 0.12%
H: 0.51%
C: 0.51%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
management company cell nurown trial therapeutics
Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
Published: 2024-03-27 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.06%
H: 0.0%
C: 0.0%
MRNA | News S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: 2.02%
H: 1.41%
C: 0.92%
vaccine trials
FDA Rejects Regeneron’s Blood Cancer Therapy for Two Forms of Lymphoma
Published: 2024-03-25 (Crawled : 16:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -100.0%
H: NaN%
C: Infinity%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.42%
H: 0.0%
C: 0.0%
fda cancer blood therapy
Innovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD)
Published: 2024-03-19 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.51%
H: 0.0%
C: 0.0%
ibi302 macular trial
Clinical Trials Market Size and Global Forecast Report 2024: Industry Trends, Share, Growth, Insight, Company Analysis 2023-2030
Published: 2024-03-13 (Crawled : 15:30) - prnewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.04%
H: 0.0%
C: 0.0%
ICLR | $291.74 -0.1% -0.1% 500K
|
Health Technology
|
| O: 0.61%
H: 0.16%
C: -2.04%
company report trials global market
Clinical trials market size in US to grow by USD 5.9 billion from 2022 to 2027, The rise in the number of clinical trials of drugs is the key factor driving market growth, Technavio
Published: 2024-03-06 (Crawled : 12:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 0.0%
H: 0.8%
C: 0.8%
TMO | News | $541.52 -1.05% 0.61% 2.1M
|
Health Technology
|
| O: 0.64%
H: 1.7%
C: 0.54%
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.2%
H: 0.71%
C: 0.33%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.45%
H: 0.0%
C: 0.0%
ICLR | $291.74 -0.1% -0.1% 500K
|
Health Technology
|
| O: 2.54%
H: 0.22%
C: -2.44%
trials key market
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
Published: 2024-03-04 (Crawled : 13:00) - globenewswire.com
MLTX | $42.31 -2.76% -2.84% 230K
|
|
| O: 0.51%
H: 0.86%
C: -4.53%
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.9%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.8%
H: 0.0%
C: 0.0%
nanobody meeting trial
Cervical Cancer Global Clinical Trials Review 2024: Clinical Trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status
Published: 2024-03-01 (Crawled : 17:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: -0.43%
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: 0.59%
H: 2.06%
C: 2.06%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.27%
H: 0.0%
C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 0.28%
H: 0.75%
C: 0.4%
review cancer trials global trial
Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers
Published: 2024-02-28 (Crawled : 13:00) - globenewswire.com
TNXP | $0.1549 -2.82% -2.91% 1.4M
|
Health Technology
|
| O: 3.26%
H: 2.37%
C: -1.53%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.63%
H: 0.0%
C: 0.0%
tnx-1500 pharmaceuticals trial
Innovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA
Published: 2024-02-20 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 2.72%
H: 0.0%
C: -0.8%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 2.53%
H: 0.0%
C: 0.0%
ibi311 disease thyroid eye trial
Sanofi, Denali ALS Candidate Flops in Mid-Stage Trial
Published: 2024-02-19 (Crawled : 13:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
| Email alert
Add to watchlist
candidate als trial
Sanofi Gets Phase II MS Win, Eyes $5B in Peak Annual Sales for Pipeline
Published: 2024-02-15 (Crawled : 17:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 1.16%
H: 1.48%
C: 0.89%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.86%
H: 0.0%
C: 0.0%
sales pipeline sanofi
Medidata and Sanofi Vaccines Extend Collaboration to Improve Patient Centricity and Trial Efficiency
Published: 2024-02-06 (Crawled : 14:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.25%
H: 0.0%
C: 0.0%
collaboration trial sanofi
Experts Take a ‘Wait and See’ Approach as BTK Inhibitors Stumble in MS
Published: 2024-01-29 (Crawled : 07:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: 0.0%
Biomunex Pharmaceuticals Announces the Start of a Phase 1 Clinical Trial for Its First-in-class Bispecific Antibody for the Treatment of Cancer
Published: 2024-01-24 (Crawled : 15:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -3.01%
H: 0.69%
C: -0.75%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.92%
H: 0.0%
C: 0.0%
antibody start cancer treatment pharmaceuticals trial
6 Neuro Data Readouts to Watch in the First Half of 2024
Published: 2024-01-22 (Crawled : 07:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 1.71%
H: 0.0%
C: -0.15%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.21%
H: 0.0%
C: 0.0%
first
Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease
Published: 2024-01-09 (Crawled : 16:00) - biospace.com/
SKYE | $16.865 -2.85% -2.94% 70K
|
Transportation and Warehousing
|
| O: -7.02%
H: 29.11%
C: 15.56%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
obesity disease kidney bioscience clearance trial
Innovent Announces the First Phase 3 Clinical Trial of Mazdutide in Chinese Adults with Overweight or Obesity Met the Primary and All Key Secondary Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA
Published: 2024-01-09 (Crawled : 00:00) - prnewswire.com
LLY | News | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.65%
H: 0.69%
C: -0.73%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.0%
H: 0.53%
C: -2.19%
obesity first chinese key trial
Innovent and Xuanzhu Enter into Clinical Trial Collaboration Investigating Combination Therapy of Sintilimab (PD-1 inhibitor) and A Novel ADC Candidate for Advanced Solid Tumors in China
Published: 2023-12-28 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: -1.32%
LLY | News | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.08%
H: 0.81%
C: -0.19%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.52%
H: 0.72%
C: -0.34%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.35%
H: 1.07%
C: -0.27%
candidate tumors collaboration trial advanced china therapy
Sanofi Axes Lung Cancer ADC After Phase III Trial Failure
Published: 2023-12-21 (Crawled : 18:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.1%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.08%
H: 0.0%
C: 0.0%
lung axes cancer trial sanofi
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.